Prime Medicine extends runway to 2027 after workforce cuts, faces arbitration over AATD program

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read

Key Changes

• high

  Company faces arbitration with Beam Therapeutics over AATD program rights; adverse outcome could force program shutdown, transfer to Beam, and monetary damages. Hearing concluded, awaiting decision.

  Legal Proceedings verify on EDGAR →
• high

  Cash runway extended from H1 2026 to 2027 following May 2025 workforce reduction ($3.7M savings) and CGD program deprioritization ($3.8M savings), despite $5.7M in arbitration legal costs.

  MD&A: Liquidity verify on EDGAR →
• high

  Going concern warning removed after appearing in prior filing; company no longer discloses substantial doubt about ability to continue operations beyond one year.

  Risk Factors verify on EDGAR →